Specialty pharmaceutical company Diurnal Group (LON: DNL) announced on Friday that it has received a second European grant for Alkindi.
Shares of Diurnal Group are up 0.73% following the news, at 69p.
The patent, EP2978414, is entitled “Composition Comprising Hydrocortisone”, a patent disclosing and claiming the composition of Alkindi for the treatment of paediatric patients with adrenal insufficiency (AI).
The patent provides in-market European protection until 2034 in all European Patent Convention-designated states. Patents in the same family have already been granted in the United Kingdom, Japan, Australia, Israel, South Africa, South Korea, China, India, Russia, and the United States (for Alkindi Sprinkle).
Diurnal said they feel the patent further expands its exclusivity position of Alkindi in Europe after already gaining 10 years of data and market exclusivity until 2028 through a paediatric use marketing authorisation granted by the European Commission and a previous patent.
“With the continued commercialisation of Alkindi being a core focus for Diurnal, we are pleased to receive this patent grant by the European Patent Office,” said Martin Whitaker, CEO of Diurnal.
“This patent, which builds on our strong global intellectual property position for the product, provides protection in Europe until 2034, supporting our continued commitment to provide Alkindi to paediatric patients suffering from adrenal insufficiency.”
Should you invest in Diurnal Group shares?
Diurnal Group shares are traded on the London stock exchange’s AIM market (the alternative investment market), which is the submarket specifically for smaller companies. AIM stocks are attractive to investors as they have tax advantages and smaller companies have the potential to benefit from rapid growth. But are Diurnal Group shares the best buy? Our stock market analysts regularly review the market and share their picks for high growth companies